Cognitive ERPs and EEG spectral differences were compared in three groups of children: nonreferred controls, those with a dominant hyperactivity/impulsivity factor (ADHD-Im), and those with a dominant inattentive factor (ADHD-Ia). The results from the ERP analyses indicated that the P250, P350, and P500 components differed between the groups. The most marked differences were seen with respect to the amplitude of the P500 components. In addition, the topographic foci of the P500 components for the CON and ADHD-Im groups were symmetrical, but the ADHD-Ia group featured P250 and P350 components that were biased away from the right hemisphere. Nevertheless, the P500 was found to be an effective discriminator between the groups. The combined spectral and ERP results suggest that the attention disordered children have difficulty adjusting their level of physiological arousal, and are defective with respect to controlled (or effortful) processing.
A recent study found that the gold foil electrode produces large pattern electroretinogram amplitudes, but the test-retest reliability was low. In a three-center study, we observed that 90% of 29 patients who were tested with gold foil electrodes used three times appeared to have markedly lower amplitudes than when tested with new electrodes during the same session. Across study centers, the mean of the new electrode recordings was 3.78 microV (standard deviation, 1.13 microV), versus 2.93 microV (1.29 microV) for used electrodes. This 0.85-microV reduction (22%) was statistically significant (F = 7.10 p = 0.01). Electrodes used three times demonstrated an average change in the coefficient of variation of 14% (standard deviation/mean = coefficient of variation; new, 1.13/3.78 = 30%; used, 1.29/2.93 = 44%). Two of the study sites (Houston/Indianapolis) conducted test-retest pattern electroretinograms on a total of 18 patients and found the mean evoked potential to be 3.55 microV with new electrodes and 2.82 microV with used electrodes. The coefficient of variation for the test-retest data was 30% and 47% for new and used electrodes, respectively. Light microscopy showed small cracks on the surface of the electrode, with the number and configuration of the cracks varying in each electrode. The presence of cracks is further complicated by their proximity to the tear film. These sources of variation can result in significantly different impedances. We propose that constant flexion, as a result of patient blinking, causes cracks in the thin gold surface of the electrode. Used electrodes will produce lower pattern electroretinogram amplitudes and poor test-retest reliability.(ABSTRACT TRUNCATED AT 250 WORDS)
This is the first report in humans of the effects of daily ingestion of a specific amino acid mixture, Kantroll, on cognitive event-related potentials (ERPs) associated with performance. Cognitive ERPs were generated by two computerized visual attention tasks, the Spatial Orientation Task (SOT) and Contingent Continuous Performance Task (CCPT), in normal young adult volunteers, where each subject acted as his own control for testing before and after 28-30 days of amino acid ingestion. A statistically significant amplitude enhancement of the P300 component of the ERPs was seen after Kantroll for both tasks, as well as improvement with respect to cognitive processing speeds. The enhancement of neurophysiologic function observed in this study on normal controls is consistent with the facilitation of recovery of individuals with RDS (i.e., substance use disorder, ADHD, carbohydrate bingeing) following the ingestion of the amino acid supplement, Kantroll, and warrants additional placebo-controlled, double-blind, studies to confirm and extend these results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.